The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney
disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is
the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been
shown to retard the deterioration of renal function in CKD patients through reducing the
levels of IS.
IS was reported to promote aortic calcification and stimulate the proliferation of vascular
smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With
this background, the investigators will performed the study whether AST-120 improve the
endothelial dysfunction in CKD patients.